DLBC - Diffuse Large B-cell Lymphoma

Subtype	Biology & Expression	Genomic Alterations	Clinical Features
C1: BCL6-fusion/NOTCH2	Germinal center B-cell–like (GCB); low immune infiltrate; modest proliferation	BCL6 translocations; NOTCH2 mutations; SPEN, TNFAIP3 inactivation	Intermediate prognosis; often GCB subtype
C2: TP53-deficient/Complex	High chromosomal complexity; low immune response; increased cell-cycle programs	TP53 inactivation; deletions in CDKN2A; high CNA burden	**Worst** prognosis; often ABC subtype
C3: BCL2-fusion/GC-like	GCB-like; high BCL2 signature; EZH2-driven epigenetic regulation	BCL2 translocations; EZH2 mutations; CREBBP, KMT2D mutations	Intermediate prognosis; GCB phenotype; frequent in relapsed/refractory cases
C4: ABC-like/RAT/NF-κB	Activated B-cell–like (ABC); NF-κB signaling; immune evasion	Mutations in MYD88, CD79B, TNFAIP3; MHC class I/II downregulation	Poor prognosis; enriched for ibrutinib-sensitive features
C5: BCL2+BCL6 co-altered	GCB-like; elevated oxidative phosphorylation and metabolic reprogramming	Co-alteration of BCL2 and BCL6; TP53 mutations; some MYC involvement	Poor prognosis; aggressive clinical behavior
C6: T-cell inflamed	Strong immune signature; interferon-γ–related inflammation	Few recurrent driver mutations; expression of immune checkpoint genes	Best prognosis; potentially sensitive to immunotherapies